Takeda and Insilico sign $600 million AI drug discovery agreement
Takeda and Hong Kong's Insilico Medicine reach strategic cooperation to use AI for early drug discovery. Insilico's Pharma.AI platform (including PandaOmics, Chemistry42, InClinico) will be used for target identification, molecular design and clinical trial prediction. The agreement includes approximately $60 million upfront and milestones, with total potential value of approximately $600 million. Takeda obtains global exclusive development, manufacturing and commercialization rights, and Insilico may receive tiered royalties.
Return to original text
A short introduction is retained here; the full text from the source website is not reposted. For specific wording and subsequent updates, please refer to the original article.
Open aihot.virxact.com original